FibroBiologics, Inc. (NASDAQ:FBLG – Get Free Report) insider Hamid Khoja purchased 10,000 shares of the stock in a transaction on Monday, August 12th. The shares were purchased at an average price of $1.90 per share, with a total value of $19,000.00. Following the acquisition, the insider now directly owns 11,250 shares in the company, valued at $21,375. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
FibroBiologics Trading Down 7.1 %
Shares of FibroBiologics stock traded down $0.14 during trading on Monday, hitting $1.83. 278,221 shares of the stock were exchanged, compared to its average volume of 177,141. The business’s 50-day simple moving average is $5.50. FibroBiologics, Inc. has a 12-month low of $1.77 and a 12-month high of $55.00.
FibroBiologics (NASDAQ:FBLG – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that FibroBiologics, Inc. will post -0.47 earnings per share for the current fiscal year.
Institutional Investors Weigh In On FibroBiologics
FibroBiologics Company Profile
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Read More
- Five stocks we like better than FibroBiologics
- What Does a Stock Split Mean?
- How to Invest in Silver: A Beginner’s Guide
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- Using the MarketBeat Dividend Yield Calculator
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.